Latest Impairments News

Page 4 of 98
Stanley Black & Decker raised its 2026 earnings and free cash flow guidance after tariff refunds helped drive a sharp third-quarter profit recovery. Underlying organic growth improved, but the refund accounted for a substantial portion of the quarter’s earnings lift.
Maxwell Dee
Maxwell Dee
4 Nov 2026
International Flavors & Fragrances raised the lower end of its 2026 sales and adjusted EBITDA guidance after broad-based third-quarter growth. The stronger operating result sits alongside a US$134 million pre-tax continuing-operations loss and a costly Food Ingredients separation still awaiting completion.
Victor Sage
Victor Sage
4 Nov 2026
Skyworks Solutions has begun operating as a larger RF semiconductor group after completing its Qorvo combination, targeting at least US$500 million in annual cost synergies. The deal arrives as standalone fiscal 2026 profit and cash flow declined, leaving execution and integration central to the investment case.
Victor Sage
Victor Sage
4 Nov 2026
Aptiv delivered 2% third-quarter revenue growth and returned to statutory profit, while maintaining its full-year 2026 outlook after the spin-off of its Electrical Distribution Systems business. The result was supported by North American growth and share buybacks, but adjusted EBITDA and margins declined.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Fiserv has reported a US$6.45 billion non-cash goodwill impairment, sending GAAP earnings deeply negative despite adjusted EPS of US$1.75. The payments group reaffirmed its 2026 outlook while doubling its Project Elevate savings target to US$1 billion.
Claire Turing
Claire Turing
4 Nov 2026
ADM delivered a sharp year-on-year increase in third-quarter earnings and raised its full-year adjusted EPS guidance, helped by stronger North American biofuels conditions. The company also cut its projected 2026 capital spending range, while warning that policy, trade and market factors remain fluid.
Victor Sage
Victor Sage
4 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
Gartner delivered stronger adjusted earnings and cash flow in the third quarter, while contract value growth accelerated and management raised its full-year 2026 outlook. The headline GAAP revenue decline was distorted by the sale of its Digital Markets operation.
Sophie Babbage
Sophie Babbage
4 Nov 2026
Realty Income delivered 3.7% year-on-year growth in quarterly AFFO per share and raised its 2026 AFFO guidance, while keeping its US$10.0 billion investment target intact. The net lease REIT is also expanding its European private capital platform with KKR, but leverage and modest same-store growth remain part of the equation.
Eva Park
Eva Park
3 Nov 2026
Marriott delivered broad-based third-quarter growth and lifted its full-year RevPAR forecast, while expanding its hotel pipeline to a record 634,000-plus rooms. The result also combined stronger earnings with heavier debt and substantial share buybacks.
Victor Sage
Victor Sage
2 Nov 2026
Loews Corporation (NYSE:L) reported third-quarter net income of US$306 million, down 39% from a year earlier, after CNA’s long-term care reserve review cut attributable earnings by US$125 million. Stronger hotel performance and share buybacks offered some support, but CNA’s underwriting trends remain a central concern.
Claire Turing
Claire Turing
2 Nov 2026
The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.
Victor Sage
Victor Sage
2 Nov 2026

Browse the archive

Full archive